|
Re: Not good news..
Yes - P53 in some respects seems a cancer "holy Grail". I got results of testing back yesterday confirming the p53 mutation but also showing GBR7, IDH2 and ERB3. From my reading the GBR7 is also an issue in triple negative and currently no targeted therapy or trials. I have decided that it is only now that this testing is becoming more mainstream and that we have no idea which elements are more important in driving our particular cancer's growth - therefore, Her2 treatments are still important and may have a beneficial impact and TK inhibitors too. It seems that no-one understands the interaction of all of these mechanisms. I am in Australia and trials are now limited too. I truly hope you will find something to try. I have read about the Chinese genetic treatment but skeptical also. The one I listed is now in human trial and is interesting. Merck, Roche and Sanofi are also nearing human trials but some are particular cancer not broader. Have you considered trying to access Perjeta through compassionate access? What about other tyrosine kinase inhibitors - Afatinib and neratinib if there are trials for those and avastin as an option too.
Lizbeth - thankyou for your references. I believe had my vitamin D levels been adequate when I would not have had metastasis - I believe it is truly underrated.
__________________
Amanda xx
40 year old Mum to three gorgeous kids - son 5 and daughters 8 and 11
Wife to my wonderfully supportive husband of 17 years!
22 February 2011 - Diagnosed Early Breast Cancer IDBC Stage2b (ER/PR -ve, Her2+ve +++) - 38 years old
(L) skin sparing mastectomy with tissue expander, axilla clearance (2/14 affected) clear margins.
Fec*3, Taxotere and herceptin*2 - stopped due to secondary diagnosis
June 24 2011 Stage IV - Skin met, axilla node, multiple lung lesions
Bolero3 trial - Navelbine, Hereptin weekly, daily Everolimus/Placebo
February 2012 - July 2012 Tykerb and Xeloda - skin mets resolved, Lungs initially dramatically reduced but growing again
August 2012 (turn 40!) tykerb and herceptin (denied compassionate use of TDM1) while holidaying in Italy!
September 2012 - January 2013 TDM1 as part of the Th3resa trial - lymph nodes resolved, lungs slowly progressing.
January 2013 - herceptin, carboplatin and Perjeta (compassionate access)
April 2013 - Some progression in lungs and lymph nodes - Abraxane, Herceptin and Perjeta
July 2013 - mixed response - dramatic reduction of most lung disease, progression of smaller lung nodules and cervical and hilar nodes - ? Add avastin.
|